|
Session 102
Poster Abstracts
Mechanisms of Drug Resistance: Reverse Transcriptase Inhibitors
Monday, 1:30 - 3:30 pm
Poster Hall |
600
 |
The Effect of the M184V Substitution in HIV-1 Reverse Transcriptase on DNA 3'-end and RNA 5'-end Directed Ribonuclease H Activity
Fei L. Yeh*1, L Miranda2, and D Kuritzkes1
1Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, US and 2Beth Israel Deaconess Med Ctr and Harvard Med Sch, Boston, MA, US |
601
|
Does 3'-Azidothymidine Select Mutations in the RNase H Domain of HIV-1 Reverse Transcriptase?
Jessica Brehm*1, D Koontz1, V Pathak2, N Sluis-Cremer1, and J Mellors1
1Univ of Pittsburgh, PA, US and 2NCI, Frederick, MD, US |
| 602 |
In a Paired-sample Comparison, the Presence of Thymidine Analogue Mutations, but not Other Common Nucleoside Reverse Transcriptase Inhibitor Mutations Has a Differential Effect on Emtricitabine and Lamivudine Susceptibility
Lisa Ross*1, N Parkin2, M Underwood1, P Gerondelis1, M St Clair1, and R Lanier1
1GlaxoSmithKline, Research Triangle Park, NC, US and 2Monogram Biosci, South San Francisco, CA, US |
| 603 |
A Novel and Rare Amino Acid Substitution E40F in HIV-1 Reverse Transcriptase Increases Zidovudine Resistance and Decreases Replication Capacity
Marleen Huigen*, P Van Ham, L De Graaf, C Boucher, and M Nijhuis
Univ Med Ctr, Utrecht, The Netherlands |
| 604 |
Mutation at Reverse Transcriptase Codon 214 is Antagonist to Thymidine Analogue Mutations Type 2 Profiles and Predicts Virological Response to Thymidine Analogue-contaning cART Regimens only if TAM Type 1 Profiles Are Concomitantly Detected
Alessandro Cozzi-Lepri*1, L Ruiz2, F Ceccherini-Silberstein3, A Mocroft1, A Phillips1, J Gatell4, B Ledergerber5, P Reiss6, B Clotet2, J Lundgren7, and EuroSIDA Study Group
1Royal Free and Univ Coll Med Sch, London, UK; 2Univ Autonoma de Barcelona, Spain; 3Univ of Tor Vergata, Rome, Italy; 4Univ of Barcelona, Spain; 5Univ Hosp, Zürich, Switzerland; 6Univ of Amsterdam, The Netherlands; and 7Copenhagen HIV Prgm, Hvidovre, Denmark |
| 605 |
Structural Analysis of Reverse Transcriptase Mutations at Codon 215 Explains the Predominance of T215Y over T215F in HIV-1 Variants Selected under ART
Mireille Henry*1, N Yahi2, J Fantini2, C Tourres1, and C Tamalet1
1Timone Hosp, Marseille, France and 2Sci Univ St Jerôme, France |
606
|
T215F Mutation and Abacavir or Efavirenz Use Are Linked to the L74I Mutation Selection
Marc Wirden*, A G Marcelin, J Ghosn, C Duvivier, S Dominguez, B Roquebert, A Simon, C Katlama, and V Calvez
Hosp Pitié-Salpétrière, Paris, France |
| 607 |
Phenotypic Susceptibility to Nucleoside Reverse Transcriptase Inhibitors of HIV-2 isolates with the Q151M Mutation in the Reverse Transcriptase Gene
F Damond1, G Collin1, S Matheron1, A Taieb2, P Campa3, A Benard2, G Peytavin1, G Chene2, F Brun-Vezinet1, Diane Descamps*1, and the French ANRS HIV-2 Cohort
1Hosp Bichat, Paris, France; 2Bordeaux Univ Hosp, INSERM U593, France; and 3Hosp St Antoine, Paris, France |
608
|
Molecular Characterization of HIV-1 Reverse Transcriptase Harboring the K65R and L74V Mutations
Fernando Frankel*, D Turner, B Spira, and M Wainberg
McGill Univ AIDS Ctr, Lady Davis Inst, Jewish Gen Hosp, Montreal, Canada |
| 609 |
Rapid Emergence of Drug-resistant SIV in Tenofovir-treated Macaques: Implications for Tenofovir Chemoprophylaxis against HIV
Jeffrey Johnson*1, K Van Rompay2, E Delwart3, and W Heneine1
1CDC, Atlanta, GA, US; 2Univ of California, Davis, CA,, US; and 3Univ of California, San Francisco, US |
|
